• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Pseudolaric Acid B
    Information
    CAS No. 82508-31-4 Price $70 / 20mg
    Catalog No.CFN99527Purity>=98%
    Molecular Weight432.46Type of CompoundDiterpenoids
    FormulaC23H28O8Physical DescriptionWhite cryst.
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Nicolaus Copernicus Uniwersity (Poland)
  • National Chung Hsing University (Taiwan)
  • University of Beira Interior (Portugal)
  • Donald Danforth Plant Science Ce... (USA)
  • The University of Newcastle (Australia)
  • University of Stirling (United Kingdom)
  • University of Perugia (Italy)
  • Heinrich-Heine-University Düsse... (Germany)
  • University of Canterbury (New Zealand)
  • Worcester Polytechnic Institute (USA)
  • Florida A&M University (USA)
  • More...
  • Package
    Featured Products
    Syringin

    Catalog No: CFN99282
    CAS No: 118-34-3
    Price: $80/20mg
    Isolinderalactone

    Catalog No: CFN99762
    CAS No: 957-66-4
    Price: $238/5mg
    Desmethoxy yangonin

    Catalog No: CFN90149
    CAS No: 15345-89-8
    Price: $188/20mg
    Ganoderic acid S

    Catalog No: CFN99066
    CAS No: 104759-35-5
    Price: $568/5mg
    Salvianolic acid B

    Catalog No: CFN99332
    CAS No: 115939-25-8
    Price: $80/20mg
    Biological Activity
    Description: Pseudolaric Acid B has dual antiangiogenic, anti-fungal, anti-fertility, anti-inflammatory, immunomodulatory and pro-apoptosis effects. Pseudolaric Acid B reversed the multidrug resistance of gastric neoplasm to chemotherapy drugs by downregulating the Cox-2/PKC-α/P-gp/mdr1 signaling pathway, it suppressed T lymphocyte activation through inhibition of NF-κB and p38 signaling pathways.
    Targets: NF-kB | p38MAPK | P65 | COX | PKC | P-gp | HSP (e.g. HSP90) | Caspase | VEGFR | IL Receptor | PPAR | HIF | Bcl-2/Bax | Caspase
    In vitro:
    J Asian Nat Prod Res. 2015 Apr 21:1-10.
    Synthesis and biological evaluation of pseudolaric acid B derivatives as potential immunosuppressive agents.[Pubmed: 25895444]

    METHODS AND RESULTS:
    Pseudolaric Acid B (PB) derivatives with immunosuppressive activity were found by our group. In order to find potential immunosuppressive agents with high efficacy and low toxicity, a series of novel PB derivatives were synthesized and evaluated on their immunosuppressive activities. Most of the synthesized compounds were tested in vitro on murine T and B proliferation. In particular, compound 11 exhibited excellent inhibitory activity toward murine T cells (up to 19-fold enhancement compared to that of mycophenolatemofetil) and little cytotoxicity toward normal murine spleen cells.
    CONCLUSIONS:
    These experimental data demonstrated that some of these PB derivatives have great potential for future immunosuppressive studies.
    Clin Cancer Res. 2004 Dec 15;10(24):8266-74.
    Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation.[Pubmed: 15623602 ]
    Pseudolaric Acid B (PAB), the naturally occurring diterpenoid isolated from the root bark of Pseudolarix kaempferi Gordon tree (Pinaceae), possesses potent antifungal and pregnancy-terminating effects that may be tightly associated with angiogenesis. This study was to examine its angiogenic inhibition, impact on vascular endothelial growth factor (VEGF) secretion from tumor cells and the possible mechanism of action.
    METHODS AND RESULTS:
    Angiogenesis inhibition was assessed by the human umbilical vascular endothelial cell proliferation, migration, and tube-formation assays, as well as the chorioallantoic membrane assay. ELISA, reverse transcription-PCR, and Western blotting analyses were performed to examine VEGF protein secretion, mRNA expression, and the possible mechanism in hypoxic MDA-MB-468 cells. PAB displayed potent in vitro antiangiogenic activity shown by inhibiting VEGF-stimulated proliferation and migration and fetal bovine serum-stimulated tube formation of human umbilical vascular endothelial cells in a concentration-dependent manner. Moreover, PAB (10 nmol per egg) significantly suppressed in vivo angiogenesis in the chorioallantoic membrane assay. On the other hand, PAB abrogated hypoxia-induced VEGF secretion from MDA-MB-468 cells via reducing HIF-1alpha protein. Additional analyses using LY294002 and U0126 indicated that the increase in hypoxia-inducible factor 1 (HIF-1)alpha protein level was highly dependent on phosphatidylinositol 3'-kinase and p42/p44 mitogen-activated protein kinase activities in hypoxic MDA-MB-468 cells. However, PAB treatment did not affect the active (phosphorylated) forms of Akt and Erk. Interestingly, the selective proteasome inhibitor MG-132 completely reversed the reduction of HIF-1alpha protein in the PAB-treated MDA-MB-468 cells.
    CONCLUSIONS:
    PAB displays the dual antiangiogenic activities of directly inhibiting endothelial cells and abrogating paracrine stimulation of VEGF from tumor cells due to reducing HIF-1alpha protein by promoting its proteasome-mediated degradation in MDA-MB-468 cells, which has potential clinical relevance.
    In vivo:
    J Cell Biochem. 2009 Sep 1;108(1):87-95
    Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation.[Pubmed: 19507195 ]
    Pseudolaric Acid B (PAB) is a major bioactive component of the medicinal plant Pseudolarix kaempferi. Traditional medicine practitioners in Asia have been using the roots of this plant to treat inflammatory and microbial skin diseases for centuries.
    METHODS AND RESULTS:
    In the current study, in vitro immunosuppressive effect of PAB and the underlying mechanisms have been investigated. The results showed that PAB dose-dependently suppressed human T lymphocyte proliferation, IL-2 production and CD25 expression induced by co-stimulation of PMA plus ionomycin or of anti-OKT-3 plus anti-CD28. Mechanistic studies showed that PAB significantly inhibited nuclear translocation of NF-kappaB p65 and phosphorylation and degradation of IkappaB-alpha evoked by co-stimulation of PMA plus ionomycin. PAB could also suppress the phosphorylation of p38 in the MAPKs pathway.
    CONCLUSIONS:
    Based on these evidences, we conclude that PAB suppressed T lymphocyte activation through inhibition of NF-kappaB and p38 signaling pathways; this would make PAB a strong candidate for further study as an anti-inflammatory agent.
    PLoS One. 2014 Sep 24;9(9):e107830.
    The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway.[Pubmed: 25250794]
    To investigate the inhibitory effect of Pseudolaric Acid B on subcutaneous xenografts of human gastric adenocarcinoma and the underlying molecular mechanisms involved in its multidrug resistance.
    METHODS AND RESULTS:
    Human gastric adenocarcinoma SGC7901 cells and drug-resistant SGC7901/ADR cells were injected into nude mice to establish a subcutaneous xenograft model. The effects of Pseudolaric Acid B with or without adriamycin treatment were compared by determining the tumor size and weight. Cyclo-oxygenase-2, protein kinaseC-α and P-glycoprotein expression levels were determined by immunohistochemistry and western blot. Pseudolaric Acid B significantly suppressed the tumor growth induced by SGC7901 cells and SGC7901/ADR cells. The combination of Pseudolaric Acid B and the traditional chemotherapy drug adriamycin exhibited more potent inhibitory effects on the growth of gastric cancer in vivo than treatment with either Pseudolaric Acid B or adriamycin alone. Protein expression levels of cyclo-oxygenase-2, protein kinaseC-α and P-glycoprotein were inhibited by Pseudolaric Acid B alone or in combination with adriamycin in SGC7901/ADR cell xenografts.
    CONCLUSIONS:
    Pseudolaric Acid B has a significant inhibitory effect and an additive inhibitory effect in combination with adriamycin on the growth of gastric cancer in vivo, which reverses the multidrug resistance of gastric neoplasm to chemotherapy drugs by downregulating the Cox-2/PKC-α/P-gp/mdr1 signaling pathway.
    Pseudolaric Acid B Description
    Source: The barks of Pseudolarix kaempferi Gordon.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    8,8''-Bibaicalein

    Catalog No: CFN95007
    CAS No: 135309-02-3
    Price: $418/5mg
    Nodakenetin

    Catalog No: CFN98788
    CAS No: 495-32-9
    Price: $268/10mg
    Liquiritin apioside

    Catalog No: CFN90707
    CAS No: 199796-12-8
    Price: $288/20mg
    (E)-Aldosecologanin

    Catalog No: CFN97737
    CAS No: 471271-55-3
    Price: $333/5mg
    1,5-Dicaffeoylquinic acid

    Catalog No: CFN99123
    CAS No: 30964-13-7
    Price: $298/20mg
    meso-Hannokinol

    Catalog No: CFN90864
    CAS No: N/A
    Price: $368/5mg
    Obovatol

    Catalog No: CFN95054
    CAS No: 83864-78-2
    Price: $388/5mg
    Calycosin-7-O-beta-D-glucoside

    Catalog No: CFN99141
    CAS No: 20633-67-4
    Price: $128/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.3124 mL 11.5618 mL 23.1235 mL 46.2471 mL 57.8088 mL
    5 mM 0.4625 mL 2.3124 mL 4.6247 mL 9.2494 mL 11.5618 mL
    10 mM 0.2312 mL 1.1562 mL 2.3124 mL 4.6247 mL 5.7809 mL
    50 mM 0.0462 mL 0.2312 mL 0.4625 mL 0.9249 mL 1.1562 mL
    100 mM 0.0231 mL 0.1156 mL 0.2312 mL 0.4625 mL 0.5781 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Cell Research:
    Mol Med Rep. 2013 Sep;8(3):787-93.
    Pseudolaric acid B induces apoptosis in U937 human leukemia cells via caspase-9‑mediated activation of the mitochondrial death pathway.[Pubmed: 23827970 ]
    Numerous studies have demonstrated that Pseudolaric Acid B (PAB) promotes apoptosis in several cancer cell lines. However, thus far, the effect of PAB on human leukemia cells has not been evaluated.
    METHODS AND RESULTS:
    In the present study, the antitumor activity and molecular mechanisms of PAB in human leukemia U937 cells were investigated. It was demonstrated that PAB induced U937 cell apoptosis, which was confirmed by typical morphological changes and Annexin V‑fluorescein isothiocyanate staining. PAB was observed to activate a caspase‑dependent apoptotic pathway in U937 cells through the regulation of the Bcl‑2 family protein-mediated mitochondrial pathway. Furthermore, the activities of caspase‑3 and -9 were increased following treatment with PAB.
    CONCLUSIONS:
    In conclusion, to the best of our knowledge, this study demonstrated for the first time that PAB was able to enhance the apoptosis of U937 cells, at least in part, through the activation of the mitochondrial death pathway. Moreover, the activation of caspase‑3 and -9 mediated the apoptotic induction.
    Animal Research:
    Life Sci. 2015 Jan 15;121:88-96.
    Pseudolaric acid B inhibits T-cell mediated immune response in vivo via p38MAPK signal cascades and PPARγ activation.[Pubmed: 25497712]
    Pseudolaric Acid B (PAB) has been prescribed for its potent immunomodulatory effect. However, the detail of mechanism remains to be demonstrated. The purpose of this study is to further clarify the mechanism of PAB on T-cell mediated immune response in vivo.
    METHODS AND RESULTS:
    Investigations were carried to ascertain the pharmacological effect of PAB in a delayed-type hypersensitivity (DTH) mouse model of T-cell mediated immune response. Histological assessment was examined by hematoxylin and eosin staining. Affymetrix GeneChip® Mouse Genome 430 2.0 arrays were employed to evaluate the expression profile of PAB. Western blot was performed to detect p38MAPK signal cascades, including p38MAPK, ATF-2, MK2, and HSP27. Finally, TNF-α level was analyzed by ELISA, and Jurkat T cells were treated with PAB to determine its role on PPARγ activation using a reporter gene assay. The results showed that PAB (5, 10, and 20mg/kg) could lead to a marked improvement for ear swelling and inflammatory infiltrate in DTH mice dose-dependently. According to the associated biological pathways from microarray analysis, PAB resulted in the restoration of abnormal immune-related gene expression linked to MAPK and PPAR signaling pathways. Moreover, PAB inhibited the activation of p38MAPK, ATF-2, MK2, and HSP27 significantly, as well as the production of TNF-α, which was reversed by GW9662, a specific antagonist for PPARγ. In addition, treatment with PAB also increased the transcriptional activity of PPARγ in a dose-dependent manner.
    CONCLUSIONS:
    These results provide us with novel insights into pharmacological action of PAB as a potential immunomodulator for the treatment of immune-related diseases.